CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,252 enrolled
Drug / intervention
Platinum-based chemotherapy +1 moredrug
Likely dose
Bevacizumab [Avastin] 15 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00451906
NCT00451906Phase 4Completed
CompareCT.gov

Open-label Study of Bevacizumab (AVASTIN®) in Combination With Platinum-containing Chemotherapy as First-line Treatment of Patients With Advanced or Recurrent Non-squamous Non-small Cell Lung Cancer

Hoffmann-La Roche·interventional·Posted Mar 26, 2007·Updated May 24, 2016

In Brief

A Phase 4 clinical trial evaluating Platinum-based chemotherapy and Bevacizumab [Avastin] for Non-Squamous Non-Small Cell Lung Cancer. Completed, enrolled 2,252 participants across 369 sites in 40 countries.

Detailed Summary

This single arm study will assess the safety and efficacy of Avastin combined with platinum-containing chemotherapy regimens in patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC). Avastin will be given as first-line treatment in combination with platinum-based chemotherapy or in combination with any standard of care NSCLC first-line chemotherapy used in line with the licensed national prescribing information. Eligible patients will receive Avastin (15mg/kg iv on day 1 of each 3 week cycle) concomitantly with chemotherapy. Avastin treatment will continue after completion of chemotherapy cycles until disease progression, and the target sample size is 500+ individuals.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Squamous Non-Small Cell Lung Cancer
CountriesArgentina, Australia, Austria, Bosnia and Herzegovina, Brazil, Canada, China, Colombia, Czechia, Denmark, Ecuador, Egypt, Estonia, Finland, France, Germany, Hong Kong, Hungary, Iceland, Israel, Italy, Latvia, Lebanon, Lithuania, Mexico, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Taiwan, Turkey (Türkiye), United Kingdom, Venezuela
Collaborators--

Timeline

Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 26, 2007
Enrollment StartAug 1, 2006
Primary CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.3 years ago

Interventions

Platinum-based chemotherapydrug

As prescribed

Bevacizumab [Avastin]drug

15 mg/kg IV on Day 1 of each 3 week cycle